| ALX-210-365B-C050 | 50 µg | Biotin | 567.00 USD | ![]() |
|
| Alternative Name: | Pentraxin 3, TSG14, TNF stimulated gene-14 |
| Concentration: | 1mg/ml |
| Purity Detail: | Affinity purified. |
| Formulation: | Liquid. In PBS containing 0.1% sodium azide. |
| Immunogen: | Recombinant human PTX3. |
| Source/Host: | From rabbit. |
| Specificity: | Recognizes human, mouse, rat and bovine (weak) PTX3 and chicken homolog PPTX. |
| Application: | ELISA (detection - excellent): 1:20’000. Use as detection antibody in an ELISA format together with MAb to PTX3 (Prod. No. ALX-804-464 (capture)) and PTX3 standard (Prod. No. ALX-201-124). Immunocytochemistry Immunohistochemistry |
| Long Term Storage: | -20°C |
| Use/Stability: | Once thawed store at +4°C and do not re-freeze. |
| Handling: | Avoid freeze/thaw cycles. |
| Miscellaneous/General: | Pentraxin 3 (PTX3), a member of the pentraxin family, is referred to as a long pentraxin and contains a unique PTX3 domain not found in C-reactive protein (CRP) or (Serum Amyloid P component) SAP. In contrast to CRP, PTX3 is produced from the major cell types involved in atherosclerotic lesions, namely vascular endothelial cells, vascular smooth muscle cells, macrophages, and nutrophils in response to inflammatory stimuli. Moreover, CRP is produced by the liver and represents a systemic response to local inflammation, whereas PTX3 is rapidly produced directly from damaged tissues and directly reflects the inflammatory state of the vasculature. PTX3 levels have been reported to be significantly elevated in acute myocardial infarction, and accordingly, statin treatment significantly decreases PTX3 levels. Due to the fact that PTX3 is able to reflect acute coronary syndrome (ACS) condition better than CRP, it is highly possible that PTX3 is a superior biomarker to predict future cardiovascular events. |
| Protocol: | Sandwich ELISA for PTX3 - 96 well-ELISA plates (Nunc MaxiSorp 446612) were coated with 100µl of MAb to PTX3 (human) (MNB4) (Prod. No. ALX-804-464), 1μg/ml in 100µl coating buffer (15mM carbonate buffer pH 9.6) and incubated overnight at 4°C. - After incubation, the plates were washed three times with 300µl/well of washing buffer (PBS + 0.05% Tween 20), and then 300µl of 5% dry milk in washing buffer were added to block non-specific binding. - The plates were incubated for 2 hours at room temperature and then washed three times with washing buffer. - 50µl (in duplicate) recombinant human PTX3 standard (Prod. No. ALX-201-124) (75pg/ml to 2.4ng/ml ), cell supernatants or biological fluids diluted in PBS without Ca and Mg + 2% BSA were added and then incubated for 2 hours at 37°C. - The plates were washed five times with washing buffer, and then 100µl of PAb to PTX3 (human) (Biotin) (Prod. No. ALX-210-365B) 50ng/ml in washing buffer were added in each well. - The plates were incubated for 1 hour at 37°C and then washed five times with 300µl of washing buffer. - 100 µl/well streptavidin-horseradish peroxidase diluted 1:4’000 were added and the plates incubated for 1 hour at room temperature. - After incubation the plates were washed 5 times with washing buffer and 100µl of TMB substrate solution was added to each well. After incubation for 10 min. at room-temperature, 50μl of stop-solution (1M H2SO4) was added. Subsequently, absorbance was read within 30min at 450nm. Note: Do not use heparin plasma or serum samples with this assay. EDTA samples are recommended. The detection value in serum is generally less than in plasma samples. |
